A Cost-Effectiveness Analysis for the Combination of Universal Screening at 9-10 Years Old and Reverse Cascade Screening of Relatives for Familial Hypercholesterolemia in Japan
The cost-effectiveness analysis revealed that a series of FH screenings (US in children + RCS in adult relatives) based on the Kagawa model was cost-effective.
Authors
- Mariko Harada‐Shiba (ORCID: https://orcid.org/0000-0002-7600-2059)
- Michihiro Yoshimura
- Keiji Matsunaga (ORCID: https://orcid.org/0000-0003-3611-1143)
- Katsuya Mori (ORCID: https://orcid.org/0009-0004-5000-0196)
- Isao Kamae (ORCID: https://orcid.org/0000-0002-3191-0942)
- Hayato Tada
- Sachie Inoue (ORCID: https://orcid.org/0000-0002-1198-731X)
- Akihito Uda (ORCID: https://orcid.org/0000-0002-4880-1195)
- Shinji Yokoyama (ORCID: https://orcid.org/0000-0003-0552-9168)
- Shizuya Yamashita
- Tetsuo Minamino (ORCID: https://orcid.org/0000-0002-5424-4081)
Institutions
- Kanazawa University (JP)
- Novartis (Switzerland) (CH)
- Chubu University (JP)
- Kagawa University (JP)
- Novartis (Japan) (JP)
- Center for Assessment (US)
- Food & Nutrition (NL)
- The University of Tokyo (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2025-02-13
- DOI
- https://doi.org/10.5551/jat.65181
- Citations
- 6
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 12.04
Funders
- Novartis Pharma